Patent lawsuit filed against BioNTech for Covid-19 vaccine

2 mins read
Patent lawsuit filed against BioNTech for Covid-19 vaccine

Germany-based biotechnology company CureVac filed a patent lawsuit against another German biotechnology company BioNTech and two of its subsidiaries for allegedly using mRNA technology and demanded “fair compensation”.

Patent lawsuit filed against BioNTech for Covid-19 vaccine

In a statement made by CureVac, it was stated that an application was filed against BioNTech and two subsidiaries of the company to the Düsseldorf District Court for compensation for infringement of intellectual property rights in mRNA technology.

In the statement, it was stated that CureVac has been working on the mRNA technology used in Covid-19 vaccines for more than 20 years, and fair compensation is requested from BioNTech for infringement of intellectual property rights.

In the statement, it was emphasized that CureVac did not seek injunctive relief and that the company does not intend to initiate legal action that would prevent the production, sale or distribution of the Covid-19 vaccine based on BioNTech’s mRNA technology.

Read:  Israeli war cabinet rejects Netanyahu's ceasefire terms

Long considered an obscure technology, mRNA technology became better known when it was used in vaccines during the COVID-19 pandemic.

BIONTECH EMPHASIZES “STRONG DEFENSE”

In the statement made by BioNTech, it was emphasized that intellectual property rights are valued and respected and that a “strong defense” will be made against all patent infringement allegations in the Kovid-19 vaccine.

In the statement, drawing attention to the success of BioNTech’s Covid-19 vaccine called Comirnaty, “BioNTech’s vaccine work is original and we will defend it strongly against all patent infringement claims.”

While BioNTech earned 19 billion euros in revenue from vaccines last year, it expects its revenues to fall to 17 billion euros this year.

FİKRİKADİM

The ancient idea tries to provide the most accurate information to its readers in all the content it publishes.

Leave a Reply

Your email address will not be published.

Comment moderation is enabled. Your comment may take some time to appear.